Vertex Pharmaceuticals, Inc. (VRTX) Misses Q3 EPS by 6c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
EPS Growth %: 0.0%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.13, $0.06 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $336 million versus the consensus estimate of $377.14 million.Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
